EI
NGNE icon

EAM Investors’s Neurogene NGNE Stock Holding History

EAM Investors’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-12,101
Closed -$616K – 313
2024
Q1 		$616K Buy
+12,101
New +$404K 0.1% 227

Other funds holding NGNE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

EAM Investors's NGNE Position: Q2 2024 in Review

EAM Investors sold out of Neurogene (NGNE) in Q2 2024, closing a stake of 12,101 shares — an estimated $616K sold.

EAM Investors first reported a position in NGNE in Q1 2024 and held it in 1 quarter. The position peaked at $616K in Q1 2024. 66 funds tracked by Wall St. Rank hold NGNE as of Q2 2024.

  • EAM Investors reported no remaining Neurogene position as of Q2 2024 after selling out during the quarter.
  • EAM Investors sold 12,101 Neurogene shares in Q2 2024, an estimated $616K.
  • EAM Investors first reported a position in Neurogene in Q1 2024 and held it in 1 quarter.
  • EAM Investors's Neurogene position peaked at $616K in Q1 2024.
  • 66 funds tracked by Wall St. Rank held Neurogene as of Q2 2024.

Based on EAM Investors's 13F filing for Q2 2024, filed 12 Aug 2024.